FDA Approves Yervoy for Pediatric Melanoma Population
Jason M. Broderick
Yervoy (ipilimumab) was granted approval by the Food and Drug Administration (FDA) for the treatment of pediatric patients who are 12 years old or younger and have unresectable or metastatic melanoma, according to Bristol-Myers Squibb (BMS), the manufacturer of the CTLA-4 inhibitor.
The expanded indication for Yervoy is based on data across two trials in which objective responses were observed in two of 17 patients under 12 years old with advanced melanoma. The responses included one partial response that lasted for 16 months.
The approved Yervoy dose for pediatric melanoma patients is 3 mg/kg administered intravenously over 90 minutes every three weeks for four doses.
“Metastatic melanoma is extremely rare in children and adolescents, which makes it particularly difficult to investigate in clinical trials. Though designing clinical trials in small pediatric populations can be challenging, this group of investigators committed to bringing a new therapy to those in need,” Lia Gore, M.D., University of Colorado School of Medicine and Children’s Hospital of Colorado, said in a statement. “Ipilimumab’s approval represents the culmination of a long effort and gives physicians the ability to expand immuno-oncology — one of the most exciting areas of medicine — for the treatment of young adults with metastatic melanoma.”
The pivotal Yervoy pediatric trials included a dose-finding study involving 33 patients aged two to 21 years with relapsed/refractory solid tumors, and a single-arm, open-label trial that accrued 12 patients aged 12 to 16 years with stage 3/4 melanoma, either previously treated or untreated.
In the dose-finding trial, the median age was 13 years, and 20 of the patients were at least 12 years old. Patients received Yervoy intravenously at doses of 1, 3, 5 and 10 mg/kg over 90 minutes every three weeks for four doses, and then every 12 weeks thereafter until progression or discontinuation.
The 12 patients in the single-arm trial were administered intravenous Yervoy at 3 mg/kg (4 patients) or 10 mg/kg (eight patients) over 90 minutes every three weeks for 4 doses.
According to BMS, the safety profile of Yervoy in children and adolescent patients was comparable to the safety profile in adult patients. Additionally, BMS noted in a press release that, “Based on a population pharmacokinetic analysis using available pooled data from 565 patients from four phase 2 adult studies (521 patients) and two pediatric studies (44 patients), body weight normalized clearance of Yervoy is comparable between adult and pediatric subjects.”
“When my daughter was diagnosed with melanoma, our entire family was devastated,” Brenda Busby, mother to a 12-year-old patient and pediatric program coordinator, Melanoma Research Foundation, said in a statement. “As someone who has lived with the many challenges of pediatric cancer, I know how important it is for patients and their families who face metastatic melanoma to have access to new therapies.”
Also commenting on the expanded pediatric indication, Chris Boerner, Ph.D., president and head of US commercial operations, BMS, said, “Despite significant advancements in oncology research for adults in recent years, treatment options continue to be limited for pediatric patients with metastatic melanoma. At Bristol-Myers Squibb, we are committed to providing meaningful support to the pediatric oncology community. This latest approval of Yervoy exemplifies our ongoing effort to expand the availability of therapies for younger cancer patients.”
Yervoy was previous approved for adult patients with unresectable or metastatic melanoma, as well as for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.